Insight

Julie Hallet: 1 of 3 PNETs potentially over-treated especially small PNETs in expert centre

Photo taken from Julie Hallet/LinkedIn

Aug 12, 2024, 12:22

Julie Hallet: 1 of 3 PNETs potentially over-treated especially small PNETs in expert centre

Julie Hallet, Chair, Equity Diversity and Inclusion Group at IHPBA, shared a post by Giovanni Marchegiani, at

“1 of 3 PNETs potentially over-treated especially small PNETs in expert centre (higher elsewhere) Same OS over vs appropriate treatment 25% overtreated pts have unnecessary morbidity.

We can harm patients NET MCC over treatment One of my fave this year.“

Quoting Giovanni Marchegiani’s post:

“Surgery for non functioning pancreatic neuroendocrine tumors.

Are we harming our patients.

Almost 400 resected P-NET with path and FU analysis %

Inadequate treatment (34% potential overtreatment)

Size only reliable predictor.“

Critical appraisal of the adequacy of surgical indications for non-functioning pancreatic neuroendocrine tumours

Authors: Stefano Partelli, Anna Battistella, Valentina Andreasi, Francesca Muffatti, Domenico Tamburrino, Nicolò Pecorelli, Stefano Crippa, Gianpaolo Balzano, and Massimo Falconi.

For more information.

Source: Julie Hallet/X and Giovanni Marchegiani/X

Anna Battistella cancer Gianpaolo Balzano Giovanni Marchegiani Julie Hallet Massimo Falconi OncoDaily Oncology PNETs Stefano Crippa Stefano Partelli Valentina Andreasi

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage